Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
Joseph Therriault, Tharick A. Pascoal, Firoza Z Lussier, et al.
Nature Aging (2022) Vol. 2, Iss. 6, pp. 526-535
Open Access | Times Cited: 166

Showing 1-25 of 166 citing articles:

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 426
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
Joseph Therriault, Marie Vermeiren, Stijn Servaes, et al.
JAMA Neurology (2022) Vol. 80, Iss. 2, pp. 188-188
Open Access | Times Cited: 152
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
João Pedro Ferrari‐Souza, Pâmela C.L. Ferreira, Bruna Bellaver, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 11, pp. 4781-4789
Open Access | Times Cited: 85
Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
Joseph Therriault, Stijn Servaes, Cécile Tissot, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 11, pp. 4967-4977
Open Access | Times Cited: 81
Predicting amyloid PET and tau PET stages with plasma biomarkers
Clifford R. Jack, Heather J. Wiste, Alicia Algeciras‐Schimnich, et al.
Brain (2023) Vol. 146, Iss. 5, pp. 2029-2044
Open Access | Times Cited: 75
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 71
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 232-244
Closed Access | Times Cited: 51
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
Gemma Salvadó, Kanta Horie, Nicolas R. Barthélemy, et al.
Nature Aging (2024) Vol. 4, Iss. 5, pp. 694-708
Open Access | Times Cited: 36
Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
Joseph Therriault, Nicholas J. Ashton, Ilaria Pola, et al.
EBioMedicine (2024) Vol. 102, pp. 105046-105046
Open Access | Times Cited: 25
Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
Pascual Sánchez-Juan, Elizabeth Valeriano-Lorenzo, Alicia Ruiz-González, et al.
Brain (2024) Vol. 147, Iss. 5, pp. 1667-1679
Open Access | Times Cited: 19
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
Joseph Therriault, Marcel S. Woo, Gemma Salvadó, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 16
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer’s disease
Karly Alex Cody, Rebecca E. Langhough, Matthew Zammit, et al.
Brain (2024) Vol. 147, Iss. 6, pp. 2144-2157
Closed Access | Times Cited: 15
Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease
Tohidul Islam, Emily Hill, Eric E. Abrahamson, et al.
Nature Medicine (2025)
Open Access | Times Cited: 3
Staging of Alzheimer’s disease: past, present, and future perspectives
Joseph Therriault, Eduardo R. Zimmer, Andréa Lessa Benedet, et al.
Trends in Molecular Medicine (2022) Vol. 28, Iss. 9, pp. 726-741
Open Access | Times Cited: 64
The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death
Dietmar Rudolf Thal, Sandra O. Tomé
Brain Research Bulletin (2022) Vol. 190, pp. 204-217
Open Access | Times Cited: 46
Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
Mona‐Lisa Malarte, Per‐Göran Gillberg, Amit Kumar, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 3, pp. 1272-1283
Open Access | Times Cited: 38
The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
Arthur C. Macedo, Cécile Tissot, Joseph Therriault, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 8, pp. 1171-1178
Open Access | Times Cited: 30
Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions
Jessica Alber, Femke H. Bouwman, Jurre den Haan, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 1, pp. 728-740
Open Access | Times Cited: 27
Cryo-EM structure of Alzheimer’s disease tau filaments with PET ligand MK-6240
Peter Kunach, Jaime Vaquer‐Alicea, Matthew S. Smith, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease
Fabio Casciano, Enrico Zauli, Claudio Celeghini, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1689-1689
Open Access | Times Cited: 11
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
Wagner S. Brum, Nicholas Cullen, Joseph Therriault, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer’s disease and other neurodegenerative diseases
Masanori Kurihara, Tomoyasu Matsubara, Satoru Morimoto, et al.
Acta Neuropathologica Communications (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability
Joseph Therriault, Shorena Janelidze, Andréa Lessa Benedet, et al.
Nature Aging (2024) Vol. 4, Iss. 11, pp. 1529-1537
Open Access | Times Cited: 9
CSF proteomics identifies early changes in autosomal dominant Alzheimer’s disease
Yuanyuan Shen, Jigyasha Timsina, Gyujin Heo, et al.
Cell (2024) Vol. 187, Iss. 22, pp. 6309-6326.e15
Open Access | Times Cited: 8
Associations of hippocampal volumes, brain hypometabolism, and plasma NfL with amyloid, tau, and cognitive decline
Fengfeng Pan, Qi Huang, Chu‐Chung Huang, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top